FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations

被引:45
作者
Amicarelli, Giulia
Shehi, Erlet
Makrigiorgos, G. Mike
Adlerstein, Daniel
机构
[1] DiaSorin SpA, I-13040 Saluggia, Italy
[2] Harvard Univ, Sch Med, Dana Faber Brigham & Womens Canc Ctr, Boston, MA USA
关键词
D O I
10.1093/nar/gkm809
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Real-time signal generation methods for detection and characterization of low-abundance mutations in genomic DNA are powerful tools for cancer diagnosis and prognosis. Mutations in codon 12 of the oncogene KRAS, for example, are frequently found in several types of human cancers. We have developed a novel real-time PCR technology, FLAG (FLuorescent Amplicon Generation) and adapted it for simultaneously (i) amplifying mutated codon 12 KRAS sequences, (ii) monitoring in real-time the amplification and (iii) genotyping the exact nucleotide alteration. FLAG utilizes the exceptionally thermostable endonuclease PspGI for real-time signal generation by cleavage of quenched fluorophores from the 5-end of the PCR products and, concurrently, for selecting KRAS mutations over wild type. By including peptide-nucleic-acid probes in the reaction, simultaneous genotyping is achieved that circumvents the requirement for sequencing. FLAG enables high-throughput, closed-tube KRAS mutation detection down to 0.1 mutant-to-wild type. The assay was validated on model systems and compared with allele-specific PCR sequencing for screening 27 cancer specimens. Diverse applications of FLAG for real-time PCR or genotyping applications in cancer, virology or infectious diseases are envisioned.
引用
收藏
页数:8
相关论文
共 49 条
[1]   Genotype-specific signal generation based on digestion of 3-way DNA junctions:: Application to KRAS variation detection [J].
Amicarelli, Giulia ;
Adlerstein, Daniel ;
Shehi, Erlet ;
Wang, Fengfei ;
Makrigiorgos, G. Mike .
CLINICAL CHEMISTRY, 2006, 52 (10) :1855-1863
[2]   Multiplex PCR-RFLP assay for detection of factor V Leiden and prothrombin G20210A [J].
Baris, I ;
Koksal, V ;
Etlik, O .
GENETIC TESTING, 2004, 8 (04) :381-383
[3]   Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia [J].
Baron, H ;
Fung, S ;
Aydin, A ;
Bahring, S ;
Luft, FC ;
Schuster, H .
NATURE BIOTECHNOLOGY, 1996, 14 (10) :1279-1282
[4]   Identification of N-acetyltransferase 2 genotypes by continuous monitoring of fluorogenic hybridization probes [J].
Blömeke, B ;
Sieben, S ;
Spötter, D ;
Landt, O ;
Merk, HF .
ANALYTICAL BIOCHEMISTRY, 1999, 275 (01) :93-97
[5]  
Chen XN, 1999, GENOME RES, V9, P492
[6]   Template-directed dye-terminator incorporation (TDI) assay: A homogeneous DNA diagnostic method based on fluorescence resonance energy transfer [J].
Chen, XN ;
Kwok, PY .
NUCLEIC ACIDS RESEARCH, 1997, 25 (02) :347-353
[7]   Fluorescence energy transfer detection as a homogeneous DNA diagnostic method [J].
Chen, XN ;
Zehnbauer, B ;
Gnirke, A ;
Kwok, PY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10756-10761
[8]   Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes [J].
Däbritz, J ;
Hänfler, J ;
Preston, R ;
Stieler, J ;
Oettle, H .
BRITISH JOURNAL OF CANCER, 2005, 92 (02) :405-412
[9]   Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].
Di Fiore, F. ;
Blanchard, F. ;
Charbonnier, F. ;
Le Pessot, F. ;
Lamy, A. ;
Galais, M. P. ;
Bastit, L. ;
Killian, A. ;
Sesboue, R. ;
Tuech, J. J. ;
Queuniet, A. M. ;
Paillot, B. ;
Sabourin, J. C. ;
Michot, F. ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169
[10]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909